Axsome Therapeutics
Jul 11, 2023
FDA Grants Priority Review for Zolbetuximab BLA; FDA Traditional Approval for LEQEMBI for Alzheimer’s Disease; Iovance Announces Regulatory and Clinical Updates for TIL Therapy in Advanced NSCLC; Biophytis Seeks FDA Approval to Launch Phase 3 Study of Potential Treatment of Sarcopenia; Orphan Drug Designation to Marker Therapeutics’s MT-401 for AML Treatment; Axsome Therapeutics Initiates Phase 3 Trial of Solriamfetol for ADHD
Astellas Announces FDA Grants Priority Review for Zolbetuximab Biologics License Application Astellas Pharma Inc. announced that the FDA has accepted and granted Priority Review for the company's Biologics Licence Application (BLA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-target...
Read More...
Mar 22, 2019
Complex regional pain syndrome (CRPS)-A debilitating disease
Did you ever feel chronic pain that is characterized by progressively worsening spontaneous regional pain without dermatomal distribution? If you did, then you might be suffering from Complex regional pain syndrome (CRPS). It is distinguished from other chronic pain conditions by the presence of signs indicatin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
